Gastric Cancer Risk in Patients With Premalignant Gastric Lesions: A Nationwide Cohort Study in the Netherlands

Gastric Precancerous Lesions in First Degree Relatives of Patients with Known Gastric Cancer: a Cross-Sectional Prospective Study in Guilan Province, North of Iran

“…Guilan province is considered a high prevalence area for gastric cancer in Iran, the prevalence of infection in our study was 78%, and this prevalence is more than what found in a large study in Netherlands (De Vries et al, 2007).…”

“…Gastric cancer is a major public health as the fourth most common cancer and second leading cause of cancerrelated death in the world (De Vries et al, 2007;Motta et al, 2008;Herszényi and Tulassay, 2010;Yaghoobi et al, 2010). According to recent studies, about 7300 to gastric cancer annually (Mehrabian etal., 2010).…”

Evidence for Extensive Pleiotropy Among Pharmacogenes

“…In this European-American cohort, rs4244285 was associated with gastric cancer at p = 0.03 (59 cases; OR: 1.74; 95% CI: 1.03-2.93) and with atrophic gastritis at p = 3.50 × 10 -4 (77 cases and 3366 controls; OR: 1.95; 95% CI: 1.35-2.81). Atrophic gastritis is a necessary precursor to gastric adenocarcinoma, and the severity of atrophy is a major indicator of cancer risk [51]. The CYP2C19 rs12248560 T allele was also associated with hepatic cancer in European-Americans at p = 6.00 × 10 -3 (65 cases; OR: 1.84; 95% CI: 1.19-2.85).…”

Surveillance of Gastric Intestinal Metaplasia: Is It Warranted?

“…Polymnia Galiatsatos atrophic gastritis (AG), 0.25% for IM, 0.6% for presence of mild to moderate dysplasia, and 6% for severe dysplasia [5] . A Japanese trial quoted a 6-fold increased risk of gastric cancer in the presence of IM [6] , while in a Korean trial the relative risk varied from 7.52 to 9.25 depending on the location of IM, lesser curve being worse than antrum [7] .…”